Celldex Therapeutics (CLDX): Assessing Valuation After a Recent Share Price Uptick

Celldex Therapeutics (CLDX) has been back on traders radar after a recent bump in the share price, leaving many investors wondering whether this clinical stage biotech is quietly setting up for its next move.

See our latest analysis for Celldex Therapeutics.

With the latest uptick to about $25.60, Celldex’s 30 day share price return of 2.73 percent and modest 90 day gain hint at cautiously improving momentum, even as the 3 year total shareholder return of negative 41.96 percent reminds investors this has been a volatile, high risk ride overall.

If Celldex’s rebound has you rethinking your healthcare exposure, it could be a good moment to scout other opportunities using our curated healthcare stocks.

With shares still trading at less than half of the average analyst price target despite solid top line growth, is Celldex a misunderstood growth story in its early innings, or has the market already baked in the next leg higher?

Price to Book of 2.8x: Is it justified?

Celldex trades at a price to book ratio of 2.8 times, which leaves the stock looking modestly valued against some peers yet not outright cheap.

The price to book multiple compares the company’s market value to its net assets and is often used for early stage or unprofitable biotechs where earnings are not yet meaningful. For Celldex, which remains loss making and still in the clinic, this lens helps investors gauge how much optimism is embedded in the balance sheet rather than current profits.

On one hand, Celldex is described as good value versus its peer average price to book ratio of 4.3 times. This suggests investors are not paying top tier biotech premiums for its pipeline potential. On the other hand, the shares are flagged as expensive relative to the broader US biotech industry average of 2.6 times. This underlines how the market is already assigning a slight valuation premium compared to the sector at large.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to Book of 2.8x (ABOUT RIGHT)

However, investors still face classic biotech risks, including trial setbacks for Barzolvolimab or CDX 622, and potential dilution if Celldex taps markets to fund development.

Find out about the key risks to this Celldex Therapeutics narrative.

Build Your Own Celldex Therapeutics Narrative

If you see the story differently or want to dive into the numbers yourself, you can craft a personalized view in just a few minutes: Do it your way.

A great starting point for your Celldex Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas before you move on?

Before you lock in any decision on Celldex, spend a few focused minutes using the Simply Wall Street Screener to uncover fresh, data backed opportunities you might otherwise miss.

• Target portfolio income by scanning for companies in these 13 dividend stocks with yields > 3% that combine attractive yields with underlying business strength.
• Explore potential mispriced opportunities by reviewing these 914 undervalued stocks based on cash flows where market pessimism may have opened the door to compelling upside.
• Track the next wave of AI driven innovation by following businesses featured in these 25 AI penny stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com